No approved hantavirus vaccine exists for New World strains like Andes virus (ANDV) or Sin Nombre virus in the Americas or Europe as of September 2026, with only inactivated candidates licensed regionally in Asia for Old World viruses causing hemorrhagic fever with renal syndrome. All advanced candidates remain in preclinical stages or early Phase 1 trials, including mRNA platforms showing single-dose protection in Syrian hamster models and a completed DNA vaccine Phase 1 demonstrating neutralizing antibodies; none have entered Phase 3 efficacy studies. The rarity of cases complicates large-scale trials needed for licensure, while standard regulatory timelines from current development phases exceed the remaining months of 2026 even under accelerated pathways. Recent outbreaks have heightened visibility but triggered no emergency funding or trial acceleration comparable to prior pandemic responses. A sudden regulatory breakthrough or redefined approval criteria for existing Asian products represent the only low-probability paths to a 2026 yes outcome.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% 概率
$136,375 交易量
$136,375 交易量
2026-12-31
4% 概率
$136,375 交易量
$136,375 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for New World strains like Andes virus (ANDV) or Sin Nombre virus in the Americas or Europe as of September 2026, with only inactivated candidates licensed regionally in Asia for Old World viruses causing hemorrhagic fever with renal syndrome. All advanced candidates remain in preclinical stages or early Phase 1 trials, including mRNA platforms showing single-dose protection in Syrian hamster models and a completed DNA vaccine Phase 1 demonstrating neutralizing antibodies; none have entered Phase 3 efficacy studies. The rarity of cases complicates large-scale trials needed for licensure, while standard regulatory timelines from current development phases exceed the remaining months of 2026 even under accelerated pathways. Recent outbreaks have heightened visibility but triggered no emergency funding or trial acceleration comparable to prior pandemic responses. A sudden regulatory breakthrough or redefined approval criteria for existing Asian products represent the only low-probability paths to a 2026 yes outcome.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$136,375结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ETThis market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for New World strains like Andes virus (ANDV) or Sin Nombre virus in the Americas or Europe as of September 2026, with only inactivated candidates licensed regionally in Asia for Old World viruses causing hemorrhagic fever with renal syndrome. All advanced candidates remain in preclinical stages or early Phase 1 trials, including mRNA platforms showing single-dose protection in Syrian hamster models and a completed DNA vaccine Phase 1 demonstrating neutralizing antibodies; none have entered Phase 3 efficacy studies. The rarity of cases complicates large-scale trials needed for licensure, while standard regulatory timelines from current development phases exceed the remaining months of 2026 even under accelerated pathways. Recent outbreaks have heightened visibility but triggered no emergency funding or trial acceleration comparable to prior pandemic responses. A sudden regulatory breakthrough or redefined approval criteria for existing Asian products represent the only low-probability paths to a 2026 yes outcome.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$136,375结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ETNo approved hantavirus vaccine exists for New World strains like Andes virus (ANDV) or Sin Nombre virus in the Americas or Europe as of September 2026, with only inactivated candidates licensed regionally in Asia for Old World viruses causing hemorrhagic fever with renal syndrome. All advanced candidates remain in preclinical stages or early Phase 1 trials, including mRNA platforms showing single-dose protection in Syrian hamster models and a completed DNA vaccine Phase 1 demonstrating neutralizing antibodies; none have entered Phase 3 efficacy studies. The rarity of cases complicates large-scale trials needed for licensure, while standard regulatory timelines from current development phases exceed the remaining months of 2026 even under accelerated pathways. Recent outbreaks have heightened visibility but triggered no emergency funding or trial acceleration comparable to prior pandemic responses. A sudden regulatory breakthrough or redefined approval criteria for existing Asian products represent the only low-probability paths to a 2026 yes outcome.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题